Why the study?
Does inhibition of the Ang II type 1 receptor or plasma kallikrein reduce retinal vascular permeability in rat models of diabetes and hypertension?
Does inhibition of the Ang II type 1 receptor or plasma kallikrein reduce retinal vascular permeability in rat models of diabetes and hypertension?
Inhibition of the Ang II type 1 receptor or plasma kallikrein reduces retinal vascular permeability in rat models of diabetes and hypertension, suggesting a potential therapeutic approach for blood-retinal barrier dysfunction.
No takes yet. Share an insight, caveat, or question.
Should not change clinical practice; hypothesis-generating for AT1 or kallikrein inhibition in retinal vascular permeability.
Phipps et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: